Cathie Wood is investing heavily in a fast-growing company, prompting the question: should you follow suit?
Illumina Remains a Promising Growth Stock in Genomics
Illumina (ILMN), a leading biotechnology company specializing in genome sequencing, has caught the attention of investors, particularly after Cathie Wood's ARK Invest significantly increased its stake to $32 million. This move positions Illumina as the 15th largest holding in ARK Invest's Genomic Revolution ETF (ARKG), reflecting Wood's high conviction in Illumina as a growth stock in the transformative genomics sector.
The company's strong positioning in genomic science and technology is evident in its wide range of products, including sequencing machines, software, and reagents, which are used in hospitals, clinics, research institutions, and various industries. This strategic role in advancing genomic sequencing technologies makes Illumina a compelling watchlist candidate for those focusing on disruptive innovations in healthcare and biotech.
Recent fundamentals show some stability and growth potential. In the first quarter, Illumina exceeded revenue expectations and reaffirmed full-year guidance. The company also reported a positive free cash flow of $208 million during the quarter. Despite a slight drop in year-over-year revenue, earnings per share are projected to grow in the current fiscal year, and the company's valuation metrics indicate expectations for future earnings growth.
Illumina's stock price has dropped significantly since its 2021 highs, but it is currently trading close to its average target price of $106.83, with a high price estimate of $185 suggesting a potential rally of over 76.8% from current levels. This optimism is reflected in the consensus on Illumina stock, which is a "Moderate Buy."
One of the reasons for the recent drop in Illumina's stock price can be attributed to a series of self-inflicted wounds, most notably the acquisition of Grail. However, Illumina has since divested from Grail in 2024, and is now refocusing on making genome sequencing cheaper, faster, and more accessible.
Investors should note that the stock carries some risks, including recent revenue softness and market volatility typical in biotech sectors. Nevertheless, the importance of genomic technology in medicine and biotech, combined with Illumina’s leadership in the field, supports its potential for long-term growth.
Illumina will report its second-quarter earnings on July 31, and analysts predict revenue of $1.05 billion on earnings per share of $1.01 for the second quarter. For the full year, analysts predict a 3% drop in revenue but earnings growth of 72.9% to $4.24 per share, with an additional 9.5% increase expected in 2026.
With Illumina's stable balance sheet, reasonable debt-equity ratio of 0.63x, and Illumina's remaining performance obligations (RPO) totaling $891 million, of which Illumina expects to generate 83% in revenue over the next year, the company's future looks promising. The new CEO, Jacob Thaysen, will undoubtedly play a crucial role in steering Illumina towards continued success in the rapidly evolving field of genomic science and technology.
In summary, Illumina is a notable growth stock in genomics backed by investor confidence, meriting close observation for potential entry points aligned with long-term genomic science growth trends.
**Sources:**
- Yahoo Finance
- ARK Invest
- Robert W. Baird
- The Wall Street Journal
- Seeking Alpha
- Given Illumina's strategic role in advancing genomic sequencing technologies, it emerges as an attractive opportunity for those interested in disruptive innovations, not only in healthcare and biotech, but also in the broader context of science, technology, and health-and-wellness.
- Investors might consider diversifying their portfolio by incorporating stocks like Illumina, not just because of its promising growth potential in genomics, but also due to the increasing importance of technology and finance in healthcare industries, thus opening up avenues for investing in this sector.
